Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors
- 1 August 2017
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (15) , 3243-3248
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitorsBioorganic & Medicinal Chemistry Letters, 2014
- Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulationsExpert Opinion on Emerging Drugs, 2011
- Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruziJournal of Biological Chemistry, 2010
- Three-Dimensional Model of Lanosterol 14α-Demethylase from Cryptococcus neoformans : Active-Site Characterization and Insights into Azole BindingAntimicrobial Agents and Chemotherapy, 2009
- Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]Bioorganic & Medicinal Chemistry Letters, 2006
- The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug InteractionsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazoleJournal of Computer-Aided Molecular Design, 2005
- Homology Modeling of Lanosterol 14α-Demethylase ofCandida albicansandAspergillus fumigatusand Insights into the Enzyme-Substrate InteractionsJournal of Biomolecular Structure and Dynamics, 2004
- Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitorsProceedings of the National Academy of Sciences, 2001
- Practice Guidelines for the Management of Cryptococcal DiseaseClinical Infectious Diseases, 2000